Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries

Esther E Freeman, Devon E McMahon, Jules B Lipoff, Misha Rosenbach, Carrie Kovarik, Junko Takeshita, Lars E French, Bruce H Thiers, George J Hruza, Lindy P Fox, American Academy of Dermatology Ad Hoc Task Force on COVID-19, Esther E Freeman, Devon E McMahon, Jules B Lipoff, Misha Rosenbach, Carrie Kovarik, Junko Takeshita, Lars E French, Bruce H Thiers, George J Hruza, Lindy P Fox, American Academy of Dermatology Ad Hoc Task Force on COVID-19

Abstract

Background: Increasing evidence suggests pernio-like lesions are cutaneous manifestations of coronavirus infectious disease 2019 (COVID-19).

Objective: To describe clinical and pathologic findings of pernio-like lesions in patients with confirmed or suspected COVID-19.

Methods: An international dermatology registry was circulated to health care providers worldwide through the American Academy of Dermatology, International League of Dermatologic Societies, and other organizations.

Results: We documented 505 patients with dermatologic manifestations associated with COVID-19, including 318 (63%) with pernio-like lesions. Patients with pernio-like lesions were generally young and healthy, with relatively mild COVID-19. Of 318 patients with confirmed or suspected COVID-19 by providers, 23 (7%) were laboratory-confirmed COVID-19 positive, and 20 others (6%) were close contacts of patients with confirmed COVID-19. Given current testing criteria, many patients lacked COVID-19 testing access. For 55% of patients, pernio-like lesions were their only symptom. In patients with other COVID-19 symptoms, pernio-like lesions typically appeared after other symptoms. Pernio-like lesions lasted a median of 14 days (interquartile range, 10-21 days).

Limitations: A case series cannot estimate population-level incidence or prevalence. In addition, there may be confirmation bias in reporting. We cannot exclude an epiphenomenon.

Conclusions: Pernio-like skin changes of the feet and hands, without another explanation, may suggest COVID-19 infection and should prompt confirmatory testing.

Keywords: COVID-19; chilblains; dermatology; pernio; public health.

Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Figures

Fig 1
Fig 1
Pernio-like lesions on the (A-F) toes and (G) fingers in (A, C, D, E) COVID-19 polymerase chain reaction-positive patients, (E, F) antibody-positive patients, and (B, G) close contacts of COVID-19 polymerase chain reaction-positive patients.

References

    1. Galvan Casas C., Catala A., Carretero Hernandez G. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. 2020. [e-pub ahead of print]. Br J Dermatol.
    1. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212–e213.
    1. Manalo I.F., Smith M.K., Cheeley J., Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;83(2):700.
    1. Piccolo V., Neri I., Filippeschi C. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. 2020. [e-pub ahead of print]. J Eur Acad Dermatol Venereol.
    1. Fernandez-Nieto D., Jimenez-Cauhe J., Suarez-Valle A. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol. 2020;83(1):e61–e63.
    1. Cappel J.A., Wetter D.A. Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic, 2000 to 2011. Mayo Clin Proc. 2014;89(2):207–215.
    1. Tan W., Lu Y., Zhang J. Viral kinetics and antibody responses in patients with COVID-19 [preprint] medRxiv. 2020 doi: 10.1101/2020.03.24.20042382.
    1. Abbasi J. The promise and peril of antibody testing for COVID-19. JAMA. 2020;323(19):1881–1883.
    1. Whitman J.D., Hiatt J., Mowery C.T. Test performance evaluation of SARS-CoV-2 serological assays [preprint] medRxiv. 2020 doi: 10.1101/2020.04.25.20074856.
    1. Wu F., Wang A., Liu M. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications [preprint] medRxiv. 2020 doi: 10.1101/2020.03.30.20047365.
    1. Crowson A.N., Magro C.M. Idiopathic perniosis and its mimics: a clinical and histological study of 38 cases. Hum Pathol. 1997;28(4):478–484.
    1. Zhang Y., Qin L., Zhao Y. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with disease severity in COVID-19. 2020. [e-pub ahead of print]. J Infect Dis.
    1. Fiehn C. Familial chilblain lupus-what can we learn from type I interferonopathies? Curr Rheumatol Rep. 2017;19(10):61.
    1. Magro C., Mulvey J.J., Berlin D. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. 2020. [e-pub ahead of print]. Transl Res.
    1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
    1. Yang X., Yu Y., Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.
    1. Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
    1. Zhang Y., Xiao M., Zhang S. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.
    1. Oxley T.J., Mocco J., Majidi S. Large-vessel stroke as a presenting feature of Covid-19 in the Young. N Engl J Med. 2020;382(20):e60.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere